ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

November 24, 2017: By Jon Swedien

ProQRProQR Therapeutics announced Nov. 13 that the first patient has been dosed in its Phase I/II open-label trial of QR-110, a proposed treatment for Leber’s congenital amaurosis 10 (LCA 10).

The trial will enroll about six adults and six children who have LCA 10 due to a p.Cys998X mutation in the CEP290 gene, ProQR said. Subjects will receive a dose of QR-110 every three months for a total of four doses in one eye.

The trial is being conducted at the University of Iowa in Iowa City, Iowa; the Scheie Eye Institute at the University of Pennsylvania in Philadelphia; and Ghent University Hospital in Ghent, Belgium.

LCA 10 is caused by mutations in the CEP290 gene, of which the p.Cys998X mutation is the most common. It leads to early loss of vision, causing most people to lose their sight in the first few years of life. To date, there are no approved treatments or other products in clinical development that treat the underlying cause of the disease, ProQR said.

QR-110 is ProQR’s lead program in the ophthalmology pipeline. The pipeline also includes two programs for Usher syndrome, a program for Fuchs endothelial corneal dystrophy, and a program for Stargardt disease. QR-110 is ProQR’s second program to enter clinical development. It follows QR-010, which is being developed for the most common mutation causing cystic fibrosis.

Netherlands-based ProQR said at the end of Q3-2017 that it had $46.6 million on hand. The company said it raised about $20 million from an issuance of ordinary shares in November that will fund operations through potential clinical data readouts in three different programs.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT